Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Share-based Compensation for 15 consecutive years, with $15.5 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 36.82% year-over-year to $15.5 million; the TTM value through Mar 2026 reached $56.7 million, up 26.15%, while the annual FY2025 figure was $52.6 million, 22.65% up from the prior year.
  • Share-based Compensation hit $15.5 million in Q1 2026 for Agios Pharmaceuticals, up from $14.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.5 million in Q1 2026 and bottomed at $9.1 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $12.1 million, with a median of $11.5 million recorded in 2022.
  • Year-over-year, Share-based Compensation crashed 34.63% in 2023 and then skyrocketed 36.82% in 2026.
  • Agios Pharmaceuticals' Share-based Compensation stood at $11.5 million in 2022, then increased by 20.49% to $13.8 million in 2023, then dropped by 21.07% to $10.9 million in 2024, then increased by 29.54% to $14.1 million in 2025, then increased by 10.03% to $15.5 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $15.5 million, $14.1 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.